GILEAD SCIENCES, INC. is 49.8x more valuable than Beam Therapeutics Inc. by market capitalization ($151.05 B vs $3.03 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BEAM | GILD |
|---|---|---|
| Market cap | $3.03 B | $151.05 B |
| US-listed rank | #1789 | #99 |
| Revenue (latest FY) | $139.74M | $29.44B |
| Net income (latest FY) | -$79.99M | $8.51B |
| Net margin | -57.2% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 488 | 981 |
GILEAD SCIENCES, INC. is 49.8x more valuable than Beam Therapeutics Inc. by market capitalization ($151.05 B vs $3.03 B).
In their latest fiscal years, Beam Therapeutics Inc. reported $139.74M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Beam Therapeutics Inc. and GILEAD SCIENCES, INC., or browse the full rankings.